123 related articles for article (PubMed ID: 37427650)
21. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
22. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
23.
Donato P; Morton A; Yaxley J; Ranasinghe S; Teloken PE; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Roberts MJ
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1843-1851. PubMed ID: 31912257
[TBL] [Abstract][Full Text] [Related]
24. Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
Hu X; Wu Y; Yang P; Wang J; Wang P; Cai J
Int Braz J Urol; 2022; 48(6):891-902. PubMed ID: 34003611
[TBL] [Abstract][Full Text] [Related]
25. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
[TBL] [Abstract][Full Text] [Related]
26. 68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions.
Kurash MM; Gill R; Khairulin M; Harbosh H; Keidar Z
Sci Rep; 2020 Feb; 10(1):3109. PubMed ID: 32080309
[TBL] [Abstract][Full Text] [Related]
27. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
28. Detection of Diffuse Peritoneal and Omental Metastases From Prostate Cancer With 18F-PSMA-1007 PET/CT.
Ji X; Wang L; Lin J; Tang K
Clin Nucl Med; 2022 Jan; 47(1):e74-e76. PubMed ID: 34238806
[TBL] [Abstract][Full Text] [Related]
29. The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer.
Ben Shimol J; Lewin R; Symon Z; Rosenzweig B; Leibowitz-Amit R; Eshet Y; Domachevsky L; Davidson T
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612859
[TBL] [Abstract][Full Text] [Related]
30. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
Leitsmann C; Thelen P; Schmid M; Meller J; Sahlmann CO; Meller B; Trojan L; Strauss A
Int Braz J Urol; 2019; 45(3):459-467. PubMed ID: 30901173
[TBL] [Abstract][Full Text] [Related]
31. 68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?
Dekalo S; Kuten J; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O
Urol Oncol; 2019 Sep; 37(9):574.e19-574.e24. PubMed ID: 31204017
[TBL] [Abstract][Full Text] [Related]
32. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
33. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
[TBL] [Abstract][Full Text] [Related]
34. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
35. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
36. Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study.
Mattiolli AB; Santos A; Vicente A; Queiroz M; Bastos D; Herchenhorn D; Srougi M; Peixoto FA; Morikawa L; da Silva JLF; Etchebehere E
Int Braz J Urol; 2018; 44(5):892-899. PubMed ID: 30088720
[TBL] [Abstract][Full Text] [Related]
37. Lumbar Osteophyte Avid on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Jochumsen MR; Madsen MA; Gammelgaard L; Bouchelouche K
Clin Nucl Med; 2018 Jun; 43(6):456-457. PubMed ID: 29538033
[TBL] [Abstract][Full Text] [Related]
38.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
39. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
40.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
